

# Author Index for Volume 10

- Aaronson NK, 195S  
Ahmed SW, 282
- Bangdiwala SI, 167  
Baron JA, 153  
Bayrd G, 153  
Beach M, 161S  
Bjornson-Benson W, 65S  
Blackburn GL, 368  
Blanchard J, 254  
Blaufox MD, 11  
Blumenstein BA, 386  
Boissel J-P, 120S, 254  
Borhani NO, 1S, 30S  
Bristol DR, 142  
Brown KM, 40S  
Buring JE, 142S  
Buyse ME, 187S  
Buzzard IM, 368, 416  
Byar DP, 129
- Canner PL, 84S  
Chalmers I, 426  
Chlebowski RT, 368  
Cohn R, 167  
Cutler JA, 84S
- Davis B, 11  
Davis CE, 167  
DCCT Research Group, 83  
Dixon DO, 231  
Dornseif BE, 57
- Elashoff R, 368  
Elias PM, 153  
Enas GG, 57
- Fisher M, 119S  
Fleiss JL, 227, 237  
Forster JL, 40S  
Freedman L, 129  
Freedman LS, 357
- Goodman SN, 188, 209  
Gøtzsche PC, 31  
Goyan JE, 236S
- Greenberg ER, 153  
Gundert-Remy U, 231S  
Guyatt GH, 407
- Hasford J, 119S  
Hawkins BS, 108, 211  
Hawkins CM, 11  
Hazard C, 167  
Hemminki E, 290  
Hennekens CH, 142S  
Hughes MD, 209S
- Insull W Jr, 368
- Jaeschke R, 407  
Jasperse DM, 282  
Jeffery RW, 65S  
Jefferys JL, 30S  
Jochimsen P, 368
- Klimt CR, 135S  
Knatterud G, 119S, 245S  
Koepcke W, 222S  
Kopenen P, 290
- Lachin JM, 127  
Langford HG, 1S, 11  
Lenfant C, 228  
Lowe N, 153  
Lubsen J, 151S
- Mandel JS, 153  
Meier P, 161S  
Meinert CI, 1S, 257S  
Messerer D, 119S  
Miké V, 244  
Morgan TM, 234  
Moussa MAA, 378
- Nierenberg DN, 153  
Nixon DW, 368
- Oberman A, 11, 40S
- Panak E, 254  
Peto R, 426
- Peyrieux J-C, 254  
Pledger G, 97  
Pocock SJ, 209S  
Prineas RJ, 30S, 167  
Prud'homme GJ, 84S
- Rimpelä U, 290  
Rockhold FW, 57
- Sacks H, 254  
Salsburg D, 71  
Sampson CB, 57  
Scanlon EF, 368  
Schakel SF, 416  
Schlundt DG, 30S, 65S  
Schneider B, 176S  
Sievert YA, 416  
Simon R, 1  
Singer J, 407  
Skin Cancer Prevention Study Group, 153  
Spencer SK, 153  
Spiegelhalter DJ, 357  
Stevens MM, 153  
Stukel TA, 153  
Sugars C, 65S  
Swencionis C, 11  
Sylvester R, 129
- Tijssen JGP, 151S  
Tonascia J, 30S, 65S
- Uski A, 290
- Van Natta ML, 40S  
Vance JC, 153
- Wassertheil-Smoller S, 11  
Wei LJ, 127  
Wuu J, 57  
Wylie-Rosett J, 11  
Wynder EL, 368
- Yusuf S, 205
- Zimbaldi N, 11  
Zucker D, 205

---

# Subject Index for Volume 10

---

## **ADHERENCE**

Implementation of a Multicomponent Process to Obtain Informed Consent in the Diabetes Control and Complications Trial, 83

## **ADJUVANT BREAST CANCER**

Unpublished Data Summaries and the Design and Conduct of Clinical Trials: The Nutrition Adjuvant Study Experience and Commentary, 368

## **BASELINE CHARACTERISTICS AND RESULTS**

Baseline Characteristics in the Hypertension Prevention Trial, 40S  
A Critique of Recent Research on the Two-Treatment Crossover Design, 237

## **BAYESIAN METHODS**

Comparison of Bayesian with Group Sequential Methods for Monitoring Clinical Trials, 357

## **BEHAVIOR MODIFICATION**

Baseline Characteristics in the Hypertension Prevention Trial, 40S  
Design, Methods, and Rationale in the Hypertension Prevention Trial, 1S  
Quality Assurance and Monitoring in the Hypertension Prevention Trial, 84S  
Recruitment in the Hypertension Prevention Trial, 30S  
Treatment in the Hypertension Prevention Trial, 65S

## **BIAS**

Methodology and Overt and Hidden Bias in Reports of 196 Double-Blind Trials of Nonsteroidal Antiinflammatory Drugs in Rheumatoid Arthritis, 31  
Practical Problems in Interim Analyses, with Particular Regard to Estimation, 209S

## **BLOOD PRESSURE**

Baseline Characteristics in the Hypertension Prevention Trial, 40S  
Design, Methods, and Rationale in the Hypertension Prevention Trial, 1S

Quality Assurance and Monitoring in the Hypertension Prevention Trial, 84S

Recruitment in the Hypertension Prevention Trial, 30S

Treatment in the Hypertension Prevention Trial, 65S

## **BOOK REVIEW**

*Designing Clinical Research: An Epidemiologic Approach* ed. Hulley SB and Cummings SR, 125

## **BOOTSTRAP CONFIDENCE LIMITS**

Using Permutation Tests and Bootstrap Confidence Limits to Analyze Repeated Events Data from Clinical Trials, 129

## **CARRYOVER EFFECTS**

A Critique of Recent Research on the Two-Treatment Crossover Design, 237

## **CERTIFICATION**

Quality Assurance and Monitoring in the Hypertension Prevention Trial, 84S

## **CLASSIFICATION TREES**

Analysis of Clinical Trial Outcomes: Alternative Approaches to Subgroup Analysis, 176S

## **CLINICAL ALERT**

Unpublished Data Summaries and the Design and Conduct of Clinical Trials: The Nutrition Adjuvant Study Experience and Commentary, 368

## **CLINICAL TRIALS, IMPACT OF ACCEPTANCE**

Varied Acceptance of Clinical Trial Results, 135S

## **COMBINATION DRUGS**

The Role of a Placebo-Treated Control Group in Combination Drug Trials, 97

## **COMPLIANCE**

Iron Supplementation During Pregnancy—Experiences of a Randomized Trial Relying on Health Service Personnel, 290

**CONFIGURATIONS**

Designing Clinical Trials for Two-sided Multiple Comparisons with a Control, 142

**CONSENSUS CONFERENCE**

Unpublished Data Summaries and the Design and Conduct of Clinical Trials: The Nutrition Adjuvant Study Experience and Commentary, 368

**CORONARY HEART DISEASE**

Comparisons of Cause of Death Verification Methods and Costs in the Lipid Research Clinics Program Mortality Follow-up Study, 167

**COVARIATES**

Analysis of Clinical Trial Outcomes: Some Comments on Subgroup Analyses, 187S  
Choosing Covariates in the Analysis of Clinical Trials, 161S

**CROSSOVER DESIGN**

A Critique of Recent Research on the Two-Treatment Crossover Design, 237

**DATA MANAGEMENT**

Baseline Characteristics in the Hypertension Prevention Trial, 40S  
The Mid-Atlantic Oncology Program's Comparison of Two Data Collection Methods, 282  
Quality Assurance and Monitoring in the Hypertension Prevention Trial, 84S  
The Relational Database Model and Multiple Multicenter Clinical Trials, 386

**DCCT**

Implementation of a Multicomponent Process to Obtain Informed Consent in the Diabetes Control and Complications Trial, 83

**DEATHS AMONG THE ELDERLY**

Comparisons of Cause of Death Verification Methods and Costs in the Lipid Research Clinics Program Mortality Follow-up Study, 167

**DEMOGRAPHIC CHARACTERISTICS**

Baseline Characteristics in the Hypertension Prevention Trial, 40S

**DIET THERAPY**

Design, Methods, and Rationale in the Hypertension Prevention Trial, 1S

Maintenance of a Nutrient Database for Clinical Trials, 416  
Treatment in the Hypertension Prevention Trial, 65S

**DIETARY FAT**

Unpublished Data Summaries and the Design and Conduct of Clinical Trials: The Nutrition Adjuvant Study Experience and Commentary, 368

**DIETARY TRIAL**

Baseline Characteristics in the Hypertension Prevention Trial, 40S  
Design, Methods, and Rationale in the Hypertension Prevention Trial, 1S  
Quality Assurance and Monitoring in the Hypertension Prevention Trial, 84S  
Recruitment in the Hypertension Prevention Trial, 30S  
Treatment in the Hypertension Prevention Trial, 65S

**DOUBLE-BLIND**

Methodology and Overt and Hidden Bias in Reports of 196 Double-Blind Trials of Nonsteroidal Antiinflammatory Drugs in Rheumatoid Arthritis, 31

**DRUG REGULATION**

The Role of Clinical Trials in Drug Regulation, 231S

**ENROLLMENT**

Recruitment in the Hypertension Prevention Trial, 30S

**ESTIMATION**

Practical Problems in Interim Analyses, with Particular Regard to Estimation, 209S

**ETHICS**

Philosophers Assess Randomized Clinical Trials: The Need for Dialogue, 244

**EVIDENCE**

Meta-analysis and Evidence, 188  
Philosophers Assess Randomized Clinical Trials: The Need for Dialogue, 244

**FACTORIAL DESIGNS**

The Role of a Placebo-Treated Control Group in Combination Drug Trials, 97

**FEASIBILITY**

Iron Supplementation During



Pregnancy—Experiences of a  
Randomized Trial Relying on  
Health Service Personnel, 290

#### **GROUP SEQUENTIAL DESIGN AND METHODS**

Analyses of Group Sequential Clinical Trials, 222S  
Comparison of Bayesian with Group Sequential Methods for Monitoring Clinical Trials, 357  
Exact, Conditional, and Predictive Power in Planning Clinical Trials, 378  
Monitoring Versus Interim Analysis of Clinical Trials: A Perspective from the Pharmaceutical Industry, 57

#### **GROUP THERAPY**

Treatment in the Hypertension Prevention Trial, 65S

#### **HYPERTENSION**

Baseline Characteristics in the Hypertension Prevention Trial, 40S  
Design, Methods, and Rationale in the Hypertension Prevention Trial, 1S  
Quality Assurance and Monitoring in the Hypertension Prevention Trial, 84S  
Recruitment in the Hypertension Prevention Trial, 30S  
Treatment in the Hypertension Prevention Trial, 65S  
Trial of Antihypertensive Interventions and Management, 11

#### **INFORMED CONSENT**

Implementation of a Multicomponent Process to Obtain Informed Consent in the Diabetes Control and Complications Trial, 83

#### **INTERACTIONS**

Analysis of Clinical Trial Outcomes: Alternative Approaches to Subgroup Analysis, 176S  
Analysis of Clinical Trial Outcomes: Some Comments on Subgroup Analyses, 187S  
The Role of a Placebo-Treated Control Group in Combination Drug Trials, 97

#### **INTERIM ANALYSES**

Analyses of Group Sequential Clinical Trials, 222S  
Monitoring Versus Interim Analysis of Clinical Trials: A Perspective from the Pharmaceutical Industry, 57  
Practical Problems in Interim Analyses,

with Particular Regard to Estimation, 209S

#### **INTERVENTION TRIAL**

Baseline Characteristics in the Hypertension Prevention Trial, 40S  
Design, Methods, and Rationale in the Hypertension Prevention Trial, 1S  
Quality Assurance and Monitoring in the Hypertension Prevention Trial, 84S  
Treatment in the Hypertension Prevention Trial, 65S

#### **IRON PROPHYLAXIS**

Iron Supplementation During Pregnancy—Experiences of a Randomized Trial Relying on Health Service Personnel, 290

#### **LIKELIHOOD**

Meta-analysis and Evidence, 188

#### **MEASUREMENT**

Measurement of Health Status: Ascertaining the Minimal Clinically Important Difference, 407

#### **META-ANALYSIS**

Considerations for the Meta-analysis of Randomized Clinical Trials: Summary of a Panel Discussion, 254  
Meta-analysis and Evidence, 188  
Meta-analysis: Science or Religion, 257S  
Methodology and Overt and Hidden Bias in Reports of 196 Double-Blind Trials of Nonsteroidal Antiinflammatory Drugs in Rheumatoid Arthritis, 31  
Unpublished Data Summaries and the Design and Conduct of Clinical Trials: The Nutrition Adjuvant Study Experience and Commentary, 368

#### **MONITORING**

Monitoring Versus Interim Analysis of Clinical Trials: A Perspective from the Pharmaceutical Industry, 57  
Quality Assurance and Monitoring in the Hypertension Prevention Trial, 84S

#### **MONTE CARLO STUDY**

Choosing Covariates in the Analysis of Clinical Trials, 161S

#### **MULTIPLE COMPARISONS**

Designing Clinical Trials for Two-sided Multiple Comparisons with a Control, 142

**MULTIPLE TRIALS**

The Relational Database Model and Multiple Multicenter Clinical Trials, 386

**NONSTEROIDAL****ANTIINFLAMMATORY DRUGS**

Methodology and Overt and Hidden Bias in Reports of 196 Double-Blind Trials of Nonsteroidal Antiinflammatory Drugs in Rheumatoid Arthritis, 31

**NOSOLOGICAL CLASSIFICATION**

Comparisons of Cause of Death Verification Methods and Costs in the Lipid Research Clinics Program Mortality Follow-up Study, 167

**NUTRIENT CALCULATION**

Maintenance of a Nutrient Database for Clinical Trials, 416  
Treatment in the Hypertension Prevention Trial, 65S

**NUTRIENT DATABASE**

Maintenance of a Nutrient Database for Clinical Trials, 416

**NUTRITION AND CANCER**

Unpublished Data Summaries and the Design and Conduct of Clinical Trials: The Nutrition Adjuvant Study Experience and Commentary, 368

**OBSERVER AGREEMENT CHART**

Comparisons of Cause of Death Verification Methods and Costs in the Lipid Research Clinics Program Mortality Follow-up Study, 167

**ONCOLOGY GROUP**

The Relational Database Model and Multiple Multicenter Clinical Trials, 386

**OPTIMIZATION**

Optimal Two-Stage Designs for Phase II Clinical Trials, 1

**P VALUES**

Meta-analysis and Evidence, 188

**PARTICIPANT EDUCATION**

Implementation of a Multicomponent Process to Obtain Informed Consent in the Diabetes Control and Complications Trial, 83

**PERMUTATION TEST**

Using Permutation Tests and Bootstrap Confidence Limits to Analyze

Repeated Events Data from Clinical Trials, 129

**PHARMACEUTICAL INDUSTRY**

Monitoring Versus Interim Analysis of Clinical Trials: A Perspective from the Pharmaceutical Industry, 57

**PHASE II TRIALS**

Optimal Two-Stage Designs for Phase II Clinical Trials, 1  
Use of Restricted Significance Tests in Clinical Trials: Beyond the One-Versus Two-Tailed Controversy, 71

**PILOT STUDIES**

Thrombolysis in Myocardial Infarction (TIMI) Randomized Studies Versus TIMI Open Label Studies, 245S

**PLACEBO**

Iron Supplementation During Pregnancy—Experiences of a Randomized Trial Relying on Health Service Personnel, 290

**POOLING**

Meta-analysis and Evidence, 188

**POWER**

Analysis of Clinical Trial Outcomes: Alternative Approaches to Subgroup Analysis, 176S  
Exact, Conditional, and Predictive Power in Planning Clinical Trials, 378

**PRE-RANDOMIZATION**

Iron Supplementation During Pregnancy—Experiences of a Randomized Trial Relying on Health Service Personnel, 290

**PRESCRIPTION PRACTICES**

Impact of Randomized Clinical Trials on Medical Practices, 120S

**PRIMARY PREVENTION TRIAL**

Baseline Characteristics in the Hypertension Prevention Trial, 40S  
Design, Methods, and Rationale in the Hypertension Prevention Trial, 1S  
Quality Assurance and Monitoring in the Hypertension Prevention Trial, 84S

Recruitment in the Hypertension Prevention Trial, 30S

Treatment in the Hypertension Prevention Trial, 65S

**PRIOR DISTRIBUTION**

Exact, Conditional, and Predictive

- Power in Planning Clinical Trials, 378
- PROGNOSTIC FACTOR**  
Analysis of Clinical Trial Outcomes:  
Some Comments on Subgroup  
Analyses, 187S
- PROTOCOLS**  
Large Trials with Simple Protocols:  
Indications and Contraindications,  
151S
- QUALITY CONTROL**  
Quality Assurance and Monitoring in  
the Hypertension Prevention Trial,  
84S
- QUALITY OF LIFE**  
Measurement of Health Status:  
Ascertaining the Minimal Clinically  
Important Difference, 407  
Quality of Life Assessment in Clinical  
Trials: Methodologic Issues, 195S
- RANDOMIZATION TEST**  
Using Permutation Tests and Bootstrap  
Confidence Limits to Analyze  
Repeated Events Data from Clinical  
Trials, 129
- RANDOMIZED CLINICAL TRIALS**  
Impact of Randomized Clinical Trials on  
Medical Practices, 120S  
Methodologic Considerations in the  
Design and Conduct of  
Randomized Trials: The U.S.  
Physicians' Health Study, 142S
- RATIO**  
Meta-analysis and Evidence, 188
- RECRUITMENT**  
Recruitment in the Hypertension  
Prevention Trial, 30S
- RELATIONAL MODEL**  
The Relational Database Model and  
Multiple Multicenter Clinical Trials,  
386
- REPEATED EVENTS**  
Using Permutation Tests and Bootstrap  
Confidence Limits to Analyze  
Repeated Events Data from Clinical  
Trials, 129
- RESPONSIVENESS**  
Measurement of Health Status:  
Ascertaining the Minimal Clinically  
Important Difference, 407
- RHEUMATOID ARTHRITIS**  
Methodology and Overt and Hidden  
Bias in Reports of 196 Double-Blind  
Trials of Nonsteroidal  
Antiinflammatory Drugs in  
Rheumatoid Arthritis, 31
- ROUTINE HEALTH SERVICES**  
Implementation of a Multicomponent  
Process to Obtain Informed  
Consent in the Diabetes Control  
and Complications Trial, 83
- SAMPLE SIZE**  
Recruitment in the Hypertension  
Prevention Trial, 30S
- SELECTION PROCEDURES**  
Choosing Covariates in the Analysis of  
Clinical Trials, 161S  
Recruitment in the Hypertension  
Prevention Trial, 30S
- SIGNIFICANCE TESTS**  
Use of Restricted Significance Tests in  
Clinical Trials: Beyond the One-  
Versus Two-Tailed Controversy, 71
- SITE VISITS**  
Quality Assurance and Monitoring in  
the Hypertension Prevention Trial,  
84S
- SKIN CANCER PREVENTION STUDY**  
The Skin Cancer Prevention Study:  
Design of a Clinical Trial of Beta-  
Carotene Among Persons at High  
Risk for Nonmelanoma Skin  
Cancer, 153
- STATISTICAL INFERENCE**  
Considerations for the Meta-analysis of  
Randomized Clinical Trials:  
Summary of a Panel Discussion, 254  
Meta-analysis and Evidence, 188  
Philosophers Assess Randomized  
Clinical Trials: The Need for  
Dialogue, 244
- STOPPING RULES**  
Analyses of Group Sequential Clinical  
Trials, 222S  
Comparison of Bayesian with Group  
Sequential Methods for Monitoring  
Clinical Trials, 357  
Practical Problems in Interim Analyses,  
with Particular Regard to  
Estimation, 209S
- STROKE**  
The "Trials" of a Long-Term Clinical  
Trial: The Ticlopidine Aspirin  
Stroke Study and the Canadian-  
American Ticlopidine Study, 236S



**STUDY SIZE**

Large Trials with Simple Protocols:  
Indications and Contraindications,  
151S

**SUBGROUP ANALYSIS**

Analysis of Clinical Trial Outcomes:  
Alternative Approaches to  
Subgroup Analysis, 176S  
Analysis of Clinical Trial Outcomes:  
Some Comments on Subgroup  
Analyses, 187S

**SUPPORT CURVES**

Meta-analysis and Evidence, 188

**TICLOPIDINE**

The "Trials" of a Long-Term Clinical  
Trial: The Ticlopidine Aspirin  
Stroke Study and the Canadian-  
American Ticlopidine Study, 236S

**TIMI**

Thrombolysis in Myocardial Infarction  
(TIMI) Randomized Studies Versus  
TIMI Open Label Studies, 245S

**TRAINING**

Quality Assurance and Monitoring in  
the Hypertension Prevention Trial,  
84S